INTUITIVE SURGICAL INC (ISRG)
US46120E6023 - Common Stock
Overall ISRG gets a fundamental rating of 6 out of 10. We evaluated ISRG against 187 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making ISRG a very profitable company, without any liquidiy or solvency issues. ISRG is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make ISRG a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
ISRG had positive earnings in the past year.
In the past year ISRG had a positive cash flow from operations.
ISRG had positive earnings in each of the past 5 years.
Each year in the past 5 years ISRG had a positive operating cash flow.
1.2 Ratios
ISRG's Return On Assets of 12.64% is amongst the best of the industry. ISRG outperforms 93.58% of its industry peers.
Looking at the Return On Equity, with a value of 14.39%, ISRG belongs to the top of the industry, outperforming 89.30% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 11.36%, ISRG belongs to the top of the industry, outperforming 92.51% of the companies in the same industry.
ISRG had an Average Return On Invested Capital over the past 3 years of 12.21%. This is above the industry average of 8.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.64% | ||
| ROE | 14.39% | ||
| ROIC | 11.36% |
ROA(3y)11.47%
ROA(5y)11.62%
ROE(3y)13.27%
ROE(5y)13.48%
ROIC(3y)12.21%
ROIC(5y)11.96%
1.3 Margins
ISRG's Profit Margin of 28.51% is amongst the best of the industry. ISRG outperforms 96.79% of its industry peers.
In the last couple of years the Profit Margin of ISRG has declined.
ISRG has a better Operating Margin (26.29%) than 95.19% of its industry peers.
ISRG's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 66.98%, ISRG is doing good in the industry, outperforming 72.19% of the companies in the same industry.
In the last couple of years the Gross Margin of ISRG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.29% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.98% |
OM growth 3Y0.73%
OM growth 5Y-5.65%
PM growth 3Y1.22%
PM growth 5Y-3.58%
GM growth 3Y0.37%
GM growth 5Y-1.03%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ISRG is creating some value.
ISRG has more shares outstanding than it did 1 year ago.
ISRG has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 53.57 indicates that ISRG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 53.57, ISRG belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 53.57 |
ROIC/WACC1.23
WACC9.21%
2.3 Liquidity
A Current Ratio of 4.30 indicates that ISRG has no problem at all paying its short term obligations.
The Current ratio of ISRG (4.30) is better than 71.66% of its industry peers.
ISRG has a Quick Ratio of 3.42. This indicates that ISRG is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.42, ISRG is doing good in the industry, outperforming 71.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.3 | ||
| Quick Ratio | 3.42 |
3. Growth
3.1 Past
ISRG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.84%, which is quite impressive.
The Earnings Per Share has been growing by 8.97% on average over the past years. This is quite good.
Looking at the last year, ISRG shows a quite strong growth in Revenue. The Revenue has grown by 14.83% in the last year.
ISRG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.85% yearly.
EPS 1Y (TTM)25.84%
EPS 3Y19.06%
EPS 5Y8.97%
EPS Q2Q%26.03%
Revenue 1Y (TTM)14.83%
Revenue growth 3Y17.8%
Revenue growth 5Y13.85%
Sales Q2Q%16.88%
3.2 Future
The Earnings Per Share is expected to grow by 17.27% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.47% on average over the next years. This is quite good.
EPS Next Y23.02%
EPS Next 2Y18.56%
EPS Next 3Y18.09%
EPS Next 5Y17.27%
Revenue Next Year14.93%
Revenue Next 2Y15.9%
Revenue Next 3Y15.82%
Revenue Next 5Y14.47%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 78.04, ISRG can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ISRG is valued a bit cheaper than 65.24% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.73. ISRG is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 65.33, which means the current valuation is very expensive for ISRG.
Based on the Price/Forward Earnings ratio, ISRG is valued a bit cheaper than 67.91% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.83. ISRG is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.04 | ||
| Fwd PE | 65.33 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ISRG indicates a somewhat cheap valuation: ISRG is cheaper than 64.17% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ISRG is valued a bit cheaper than the industry average as 67.38% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 318.76 | ||
| EV/EBITDA | 70.32 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ISRG does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of ISRG may justify a higher PE ratio.
ISRG's earnings are expected to grow with 18.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.39
PEG (5Y)8.7
EPS Next 2Y18.56%
EPS Next 3Y18.09%
5. Dividend
5.1 Amount
ISRG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTUITIVE SURGICAL INC
NASDAQ:ISRG (12/20/2024, 8:19:06 PM)
After market: 524.43 0 (0%)524.43
+0.52 (+0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners90.55%
Inst Owner Change-0.9%
Ins Owners0.5%
Ins Owner Change-2.54%
Market Cap186.79B
Analysts81.05
Price Target556.89 (6.19%)
Short Float %0.98%
Short Ratio2.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.88%
Min EPS beat(2)10.37%
Max EPS beat(2)13.38%
EPS beat(4)4
Avg EPS beat(4)8.48%
Min EPS beat(4)4.44%
Max EPS beat(4)13.38%
EPS beat(8)7
Avg EPS beat(8)4.64%
EPS beat(12)9
Avg EPS beat(12)3.16%
EPS beat(16)13
Avg EPS beat(16)6.67%
Revenue beat(2)0
Avg Revenue beat(2)-0.1%
Min Revenue beat(2)-0.14%
Max Revenue beat(2)-0.05%
Revenue beat(4)1
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-0.76%
Max Revenue beat(4)0.12%
Revenue beat(8)2
Avg Revenue beat(8)-0.46%
Revenue beat(12)4
Avg Revenue beat(12)-0.43%
Revenue beat(16)7
Avg Revenue beat(16)1.66%
PT rev (1m)2.72%
PT rev (3m)13.18%
EPS NQ rev (1m)-0.05%
EPS NQ rev (3m)5.55%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)3.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.31%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.04 | ||
| Fwd PE | 65.33 | ||
| P/S | 23.74 | ||
| P/FCF | 318.76 | ||
| P/OCF | 102.59 | ||
| P/B | 11.99 | ||
| P/tB | 12.28 | ||
| EV/EBITDA | 70.32 |
EPS(TTM)6.72
EY1.28%
EPS(NY)8.03
Fwd EY1.53%
FCF(TTM)1.65
FCFY0.31%
OCF(TTM)5.11
OCFY0.97%
SpS22.09
BVpS43.75
TBVpS42.7
PEG (NY)3.39
PEG (5Y)8.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.64% | ||
| ROE | 14.39% | ||
| ROCE | 12.87% | ||
| ROIC | 11.36% | ||
| ROICexc | 15.6% | ||
| ROICexgc | 16.11% | ||
| OM | 26.29% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.98% | ||
| FCFM | 7.45% |
ROA(3y)11.47%
ROA(5y)11.62%
ROE(3y)13.27%
ROE(5y)13.48%
ROIC(3y)12.21%
ROIC(5y)11.96%
ROICexc(3y)19.34%
ROICexc(5y)19.83%
ROICexgc(3y)20.37%
ROICexgc(5y)21.16%
ROCE(3y)13.84%
ROCE(5y)13.55%
ROICexcg growth 3Y-1.89%
ROICexcg growth 5Y-8.22%
ROICexc growth 3Y-0.57%
ROICexc growth 5Y-7.6%
OM growth 3Y0.73%
OM growth 5Y-5.65%
PM growth 3Y1.22%
PM growth 5Y-3.58%
GM growth 3Y0.37%
GM growth 5Y-1.03%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 247.98% | ||
| Cap/Sales | 15.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 70.95% | ||
| Profit Quality | 26.12% | ||
| Current Ratio | 4.3 | ||
| Quick Ratio | 3.42 | ||
| Altman-Z | 53.57 |
F-Score5
WACC9.21%
ROIC/WACC1.23
Cap/Depr(3y)158.69%
Cap/Depr(5y)157.89%
Cap/Sales(3y)9.9%
Cap/Sales(5y)9.4%
Profit Quality(3y)72%
Profit Quality(5y)81.76%
High Growth Momentum
Growth
EPS 1Y (TTM)25.84%
EPS 3Y19.06%
EPS 5Y8.97%
EPS Q2Q%26.03%
EPS Next Y23.02%
EPS Next 2Y18.56%
EPS Next 3Y18.09%
EPS Next 5Y17.27%
Revenue 1Y (TTM)14.83%
Revenue growth 3Y17.8%
Revenue growth 5Y13.85%
Sales Q2Q%16.88%
Revenue Next Year14.93%
Revenue Next 2Y15.9%
Revenue Next 3Y15.82%
Revenue Next 5Y14.47%
EBIT growth 1Y21.07%
EBIT growth 3Y18.66%
EBIT growth 5Y7.42%
EBIT Next Year41.57%
EBIT Next 3Y25.01%
EBIT Next 5Y22.48%
FCF growth 1Y-45.49%
FCF growth 3Y-13.13%
FCF growth 5Y-5.26%
OCF growth 1Y12.35%
OCF growth 3Y6.9%
OCF growth 5Y9.17%